Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
HMG-CoA reductase inhibitors (statins) are the drugs of first choice for treating hypercholesterolaemia in order to prevent or slow the progression of coronary heart disease (CHD). Statins generally reduce the risk of CHD morbidity or mortality by about 30%. Lovastatin is effective in lowering plasma total cholesterol and low-density lipoprotein cholesterol levels, and is widely prescribed for both the primary and secondary prevention of CHD. In the major AFCAPS/TexCAPS primary prevention study of 6605 middle-aged or elderly men and women without symptomatic cardiovascular disease and with only moderately elevated serum lipids, treatment with lovastatin 20-40 mg once daily for a mean of 5.2 years significantly (p < 0.001) reduced the incidence of a first acute major cardiac event by 37% compared with placebo. In the smaller ACAPS study of 919 men and women who were asymptomatic for cardiovascular disease, but with evidence of early atherosclerosis, treatment with lovastatin for 3 years significantly (p = 0.001) slowed or reversed atherosclerosis compared with placebo, as measured by changes in the intimal-medial thickness of carotid arteries on B-mode ultrasound. Three randomised, controlled, secondary prevention trials have demonstrated that in patients with coronary artery disease, treatment with lovastatin 20-80 mg/day alone or in combination with colestipol for 2-2.5 years reduced the severity of stenosis and/or slowed or reversed the progression of atherosclerosis, as assessed by angiography. In the FATS study, the severity of stenosis after 2.5 years in recipients of lovastatin plus colestipol was reduced by 2.8% compared with placebo, while the frequency of lesion progression was halved and the frequency of lesion regression was tripled. Treatment with lovastatin for 2.2 years in the MARS study significantly reduced the mean percent diameter stenosis compared with placebo (p = 0.005) in patients with more severe stenosis, and also significantly (p = 0.002) reduced the mean global change score (indicating less progression). In the CCAIT study, lovastatin therapy for 2 years significantly improved coronary change scores (p < 0.01) and significantly reduced the incidence of new lesions (p = 0.001) compared with placebo. Across the primary and secondary prevention studies, lovastatin was shown to be similarly effective in women, the elderly, smokers and in subjects with hypertension, hypercholesterolaemia or type 2 diabetes mellitus. Therefore, the available data demonstrate that lovastatin provides significant lipid-modifying efficacy, slows progression or causes regression of atherosclerosis, and protects against acute cardiac events, in both those with and those without symptomatic CHD.
Frisinghelli
Anna
A
Divisione di Cardiologia Riabilitativa, Presidio Ospedaliero di Passirana, AO G. Salvini, Garbagnate Milanese, Milan, Italy. annafris@tin.it
Mafrici
Antonio
A
D000328:Adult; D050197:Atherosclerosis / Q000150:complications / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000379:methods; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control*; D018450:Disease Progression; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008148:Lovastatin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012107:Research Design; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008148:Lovastatin
CMAJ. 2005 Apr 26;172(9):1187-94
15851712
Am J Cardiol. 2000 Dec 1;86(11):1176-81
11090787
Am J Cardiol. 2001 May 1;87(9):1074-9
11348605
Clin Cardiol. 1996 Sep;19(9):683-9
8874986
Circulation. 1996 Aug 15;94(4):614-21
8772679
N Engl J Med. 2001 Jun 28;344(26):1959-65
11430324
Am J Manag Care. 1997 Oct;3(10):1537-45
10178460
JAMA. 1998 May 27;279(20):1615-22
9613910
J Womens Health Gend Based Med. 2001 Dec;10(10):971-81
11788107
J Am Coll Cardiol. 1998 Sep;32(3):665-72
9741509
Am J Cardiol. 1998 Mar 1;81(5):582-7
9514454
JAMA. 2007 Mar 28;297(12 ):1344-53
17384434
Presse Med. 1999 Nov 20;28(36):2002-10
10599269
Am J Cardiol. 1991 Mar 1;67(6):447-53
1998274
JAMA. 2004 Mar 3;291(9):1071-80
14996776
Circulation. 1999 Jan 19;99(2):237-42
9892589
Am J Cardiol. 1990 Sep 18;66(8):44B-55B
2206036
Circulation. 2002 Dec 17;106(25):3143-421
12485966
Clin Ther. 2006 Jan;28(1):26-35
16490577
BMJ. 2000 Mar 11;320(7236):705-8
10710586
N Engl J Med. 1990 Nov 8;323(19):1289-98
2215615
Arch Intern Med. 1991 Jan;151(1):43-9
1985608
N Engl J Med. 2005 Apr 7;352(14):1425-35
15755765
Ann Intern Med. 1996 Mar 15;124(6):548-56
8597317
Curr Opin Cardiol. 2002 Sep;17(5):503-11
12357127
Diabetes Metab Rev. 1987 Apr;3(2):463-524
3552530
Circulation. 1994 Oct;90(4):1679-87
7734010
Circulation. 2001 Mar 6;103(9):1191-3
11238259
Circulation. 1995 Nov 1;92 (9):2404-10
7586338
JAMA. 2001 May 16;285(19):2481-5
11368701
Arch Intern Med. 1993 May 10;153(9):1079-87
8481075
BMJ. 2000 Jul 22;321(7255):199-204
10903648
Circulation. 1994 Jul;90(1):42-9
8026027
JAMA. 2006 Apr 5;295(13):1556-65
16533939
Circulation. 1994 Mar;89(3):959-68
8124836
Immunol Res. 2002;25(3):271-85
12018465
Optom Vis Sci. 1993 Nov;70(11):937-43
8302530
Ann Intern Med. 1996 Dec 15;125(12):990-1000
8967711
Am J Cardiol. 1988 Nov 11;62(15):44J-49J
3055923
Arzneimittelforschung. 2003;53(9):605-11
14558433
Am Heart J. 1999 Aug;138(2 Pt 2):S177-82
10426879
Am Heart J. 2000 Apr;139(4):577-83
10740137
N Engl J Med. 2004 Apr 8;350(15):1495-504
15007110
Am J Med. 1991 Jul 31;91(1B):25S-30S
1831006
Exp Eye Res. 1990 Jan;50(1):65-78
2307197
BMJ. 2003 Jun 28;326(7404):1423
12829554
Circulation. 1999 Jul 20;100(3):230-5
10411845
N Engl J Med. 1997 Apr 3;336(14):973-9
9077376
N Engl J Med. 2000 Mar 23;342(12):836-43
10733371
Curr Opin Lipidol. 2001 Aug;12(4):391-4
11507323
Am J Med. 1991 Jul 31;91(1B):18S-24S
1867232
Am J Cardiol. 1998 Aug 27;82(4B):3J-10J
9737640
N Engl J Med. 1988 Jan 14;318(2):81-6
3422105
Ann Intern Med. 1993 Nov 15;119(10 ):969-76
8214993
Am J Cardiol. 1995 Sep 28;76(9):47C-53C
7572686